Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2021 07:00 ET | Source: Akouos, Inc.

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

The Resonate™ program provides access to a potential genetic diagnosis by offering genetic testing at no cost to eligible individuals, their insurance, or their healthcare providersA genetic diagnosis...
November 23, 2020 09:00 ET | Source: Akouos, Inc.

Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
November 12, 2020 07:00 ET | Source: Akouos, Inc.

Akouos Reports Third Quarter 2020 Financial Results and Provides Business Highlights

- Expanded leadership team with appointment of Sachiyo Minegishi as CFO and promotion of Jennifer Wellman to COO - - Continued progress towards 2021 IND submission for AK-OTOF, a gene therapy...
October 01, 2020 07:00 ET | Source: Akouos, Inc.

Akouos Announces Key Leadership Appointments

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
September 24, 2020 08:00 ET | Source: Akouos, Inc.

Akouos to Present at Upcoming October Virtual Investor Conferences

BOSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling...
September 08, 2020 08:00 ET | Source: Akouos, Inc.

Akouos to Present at Cantor Global Virtual Healthcare Conference

BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with...
August 13, 2020 07:00 ET | Source: Akouos, Inc.

Akouos Reports Second Quarter 2020 Financial Results and Provides Business Highlights

- Upsized IPO in June 2020 raised $244.4 million in gross proceeds - - Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF...
August 05, 2020 08:00 ET | Source: Akouos, Inc.

Akouos Announces Expansion of Executive Team and Board of Directors

Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Akouos,...
August 03, 2020 08:00 ET | Source: Akouos, Inc.

Akouos to Present at BTIG Virtual Biotechnology Conference

BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live...
June 30, 2020 16:05 ET | Source: Akouos, Inc.

Akouos Announces Closing of Initial Public Offering

BOSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve,...